ArticleCureus2025
Reirradiation of Large or Multifocal High-Grade Gliomas With Gyroscopic Radiosurgery in Combination With Modulated Electro-Hyperthermia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHigh-grade gliomas (HGGs) are the most common primary malignant brain neoplasms in adults, with a high rate of local relapse in the first two years after primary treatment, resulting in poor prognosis. The aim of this study is to describe the potential benefits of the implementation of gyroscopic radiosurgery (GRS) in combination with modulated electro-hyperthermia (mEHT) as a radiosensitizer for the reirradiation of large or multifocal recurrent HGGs.
methodsA study was designed to evaluate the impact of survival and clinical tolerance. Clinical information of 15 patients treated between April 2023 and September 2024 was analyzed.
resultsFifteen patients with a median age of 50 years and grade 4 (n = 13) or grade 3 (n = 2) gliomas were included in the study. The median Karnofsky Performance Status (KPS) was 70. Multifocal disease was present in 10 patients. The median time from previous radiation was 16 months. Twelve patients were eligible for analysis. The median planning target volume (PTV) was 33.6 cc; 48% (10 lesions) received five fractions (20-30 Gy), 38% (eight lesions) received one fraction (15-18 Gy), and 14% (three lesions) received three fractions (24 Gy). mEHT was applied every 48 hours. The median follow-up was seven months with no in-field recurrences reported. Actuarial overall survival (OS) from GRS and mEHT was 58.3% at six months and 25% at 12 months. Acute tolerance was acceptable, with 33.3% of patients showing improvement, 33.3% remaining stable, and 33.3% presenting grade 2 radiation necrosis, managed with outpatient steroid adjustment.
conclusionsHigh-risk, HGG reirradiation with GRS and mEHT showed a favorable impact on local control and OS with low toxicity. Longer follow-up and larger series are needed to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.